Tag Archive for: Clinical Trial

Weekly round-up: From a vaccine protein manufacturing collaboration, to the appointment of an orthopaedic devices expert…

/in

MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus and Wacker Biotech, a contract development and manufacturing organisation, on Tuesday announced a collaboration to manufacture the active protein ingredients of MinervaX’s GBS vaccine. MinervaX will scale up supply of its novel GBS vaccine, ahead of commencing phase […]

Read more

Vesper Bio announces successful Phase I study for potentially disease-modifying treatment for frontotemporal dementia

/in

VES001 is a first-in-class oral, brain penetrant, small molecule sortilin inhibitor for treatment of FTD(GRN) Data demonstrate excellent safety, tolerability profile, dose-proportionality and target engagement with elevations in progranulin in both plasma and CNS CTA filed for Phase IIa study, first dose targeted for Q4 2024 Copenhagen, Denmark, 04 September 2024 – Vesper Bio ApS […]

Read more

Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs

/in

Brings extensive experience in design, development, and implementation of US medtech clinical trial strategy for hemodialysis and vascular access Follows expansion of Xeltis’ clinical presence in the US after recent IDE approval for aXessTM US pivotal trial EINDHOVEN, The Netherlands, 23 July 2024 – Xeltis, a leading developer of transformative implants that enable the natural […]

Read more

Amber Implants Completes Enrolment of First-In-Human Clinical Trial of its VCFix® Spinal System

/in

The Hague, Netherlands, 11 June 2024: Amber Implants (‘Amber’ or ‘the Company’), an innovative medical technology company developing next-generation implants for spinal injuries, today announces that it has completed enrolment of its first-in-human clinical trial with its innovative VCFix® Spinal System. The VCFix® Spinal System is the first device that does not rely on bone […]

Read more

STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

/in

STC-15 was well tolerated and clinical activity was observed across the pharmacologically active dose range in advanced cancer patients Primary objectives were achieved to progress STC-15 into combination with checkpoint inhibitor combination studies 3 June 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, […]

Read more